Delivery of MCC950 in HNSCC mice remarkably reduced NLRP3 inflammasome activation measured as mature IL-1β release; treated mice also displayed lower tissue resident MDSCs, Treg cells and TAMs as well as increased CD4+ and CD8+ T cells, which may denotes a novel approach for HNSCC therapy [197]. This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.